Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild‑type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).

Authors

Lee Steven Schwartzberg

The West Clinic, Memphis, TN

Lee Steven Schwartzberg , Fernando Rivera , Meinolf Karthaus , Gianpiero Fasola , Jean-Luc Canon , Hua Yu , Kelly S. Oliner , William Y. Go

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 Gastrointestinal Cancers Symposium

bookmark_border

Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).

First Author: Ann-Lii Cheng

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.

First Author: Kohei Shitara

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC).

First Author: Fernando Rivera

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

First Author: Kelly S. Oliner